Immunic Inc (IMUX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.72 (+3.57%), Market cap $0.16B, 52-week low–high $0.51 ~ $12.95.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with d
Financial statements, price targets, institutional (13F) holdings and related news for Immunic Inc are updated in real time on BlackAll Trade.
Immunic Inc trades at $10.72 (+3.57%). Real-time quotes and charts are available on BlackAll Trade.
Immunic Inc has a market cap of about $0.16B.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. I